OCEAN Study for EGPA Request More Information Trial Objective People with eosinophilic granulomatosis with polyangiitis (EGPA) are needed for the OCEAN clinical trial. The study compares two medications: mepolizumab (NUCALA), which is administered by an injection once a month, and depemokimab, an investigational medication that is injected twice a year. Researchers want to understand if depemokimab is as safe and effective as mepolizumab. Volunteers will receive a blood draw and will be randomly assigned to receive an injection of one of the two medications. Enrollment This trial is active and currently recruiting. Who Can Participate Adults with EGPA that has worsened or returned after previous treatment and are taking a corticosteroid or immunosuppressant Age: 18+ Gender: Any Gender Estimated Time Commitment Once a month visits for approximately 15 months Compensation Provided Trial Contact For more information, contact: Allen Stevens 303.398.1268 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors GSK Principal Investigators Michael Wechsler, MD, MMSc + × Michael Wechsler, MD, MMSc Director, The Cohen Family Asthma Institute Professor Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine View Full Profile Patient Rating 4.9 out of 5 stars Make an Appoinment Co-Investigators Vamsi Guntur, MD, MSc + × Vamsi Guntur, MD, MSc Associate Professor Division of Pulmonary, Critical Care & Sleep Medicine Department of Medicine View Full Profile Patient Rating 4.7 out of 5 stars Make an Appoinment Request More Information First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective People with eosinophilic granulomatosis with polyangiitis (EGPA) are needed for the OCEAN clinical trial. The study compares two medications: mepolizumab (NUCALA), which is administered by an injection once a month, and depemokimab, an investigational medication that is injected twice a year. Researchers want to understand if depemokimab is as safe and effective as mepolizumab. Volunteers will receive a blood draw and will be randomly assigned to receive an injection of one of the two medications.